Philikos B.V., a Dutch biotechnology company developing antibody-based therapies to treat severe immune disorders, today announced that it has ...

THANK-u Plus demonstrates sustained expansion regardless of varying NKG2A expression levels on NK cells and exhibits significantly improved ... Handelskriege, Rekordzölle und politische Isolation ...

There is no highly effective vaccine against tuberculosis (TB), which remains an infection of global concern. Charles ...

Natural killer (NK) cells constitute the third largest lymphocyte subset, representing around 10-15% of circulating lymphocytes in blood. These large granular cells are essential to the immune ...

SENTI-202, an allogeneic CAR NK cell therapy, offers a pre-manufactured option for aggressive cancers like AML, overcoming delays associated with autologous CAR T-cell therapies. The therapy's ...

SENTI-202, a CAR NK cell therapy, achieved complete remission in several relapsed/refractory AML patients, showing potential as an effective treatment option. The off-the-shelf nature of SENTI-202 ...

This study investigates the potential involvement of mutations in the IL-36 receptor antagonist (IL36RN, IL-36RA) in the ...

The entire procedure—from single cell isolation to raw data generation—takes around five days with MATQ-seq. It is ideal for smaller samples from hundreds of cells; in this range it works very ...

The video can be accessed here. SENTI-202 is the Company’s First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy product candidate designed to selectively ...

This receptor helps prevent overactivation of immune cells that drive rejection. When this brake is missing, inflammation worsens, leading to faster rejection in preclinical models. Importantly ...